Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 15/20 | 0.68 |
| ▸ | P2RY4 | P51582 | 10/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.68 |
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2349191 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL20798009 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL27554036 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL20074354 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL48209 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL16633413 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8003 | 1.00 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Water SCHEMBL3961110 | 0.99 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Bromide SCHEMBL18112592 | 0.99 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Iodide SCHEMBL7941539 | 0.99 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-20160168636-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION | 2016-06-16 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163053-B2 | Nucleotide analogs | FLUIDIGM CORPORATION (US) | 2015-10-20 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2011-04-07 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081647-A1 | NUCLEOTIDE ANALOGS | DUT, NT5C2, NUDT21 | DUT 1/4885P2RY2 249/4885P2RY4 148/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | DUT 269/4885P2RY2 4592/4885P2RY4 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.